|
|
Volumn 34, Issue 4, 2003, Pages 837-839
|
|
Banning anticoagulation in stroke or consequence of poor study design [5] (multiple letters)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANTICOAGULANT AGENT;
HEPARIN;
HEPARINOID;
RECOMBINANT PLASMINOGEN ACTIVATOR;
ANTICOAGULANT THERAPY;
BLEEDING;
BLOOD CLOTTING PARAMETERS;
BLOOD PRESSURE MONITORING;
BRAIN ISCHEMIA;
CLINICAL RESEARCH;
CLINICAL TRIAL;
COMPUTER ASSISTED TOMOGRAPHY;
DEEP VEIN THROMBOSIS;
DIAGNOSTIC IMAGING;
DIAGNOSTIC PROCEDURE;
DRUG EFFICACY;
DRUG INDICATION;
DRUG SAFETY;
ELECTROCARDIOGRAM;
EVIDENCE BASED MEDICINE;
HUMAN;
LETTER;
LUNG EMBOLISM;
META ANALYSIS;
METHODOLOGY;
MORBIDITY;
MORTALITY;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PATIENT MONITORING;
PATIENT SELECTION;
PHYSICIAN ATTITUDE;
PRACTICE GUIDELINE;
PRESCRIPTION;
PRIORITY JOURNAL;
PROPHYLAXIS;
RECURRENT DISEASE;
RISK BENEFIT ANALYSIS;
SAMPLE SIZE;
STROKE;
TRAINING;
TREATMENT OUTCOME;
ANTICOAGULANTS;
CEREBROVASCULAR ACCIDENT;
HUMANS;
RESEARCH DESIGN;
|
|
EID: 0037384755
PISSN: 00392499
EISSN: None
Source Type: Journal
DOI: 10.1161/01.STR.0000061517.79104.0E Document Type: Letter |
|
Times cited : (2)
|
|
References (0)
|
